How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop? Eli Lilly ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers ...

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.

Eli Lilly and Company (NYSE:LLY) executives highlighted strong 2025 performance, continued demand for its incretin medicines, ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Eli Lilly and Company (NYSE:LLY) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Goldman Sachs ...

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...

A global pharmaceutical company is moving into Center City next year — and it could be a “game-changing” development for Philly’s biotech scene, a leader in the space says. “We see it as a ...

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

The investment supports Eli Lilly and Company’s $3.5 billion expansion into Upper Macungie Township, marking the largest private-sector investment in Lehigh Valley history.